Literature DB >> 18093712

Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents.

Qun Xu1, Li-Tao Yi, Ying Pan, Xing Wang, Yu-Cheng Li, Jian-Mei Li, Cai-Ping Wang, Ling-Dong Kong.   

Abstract

Honokiol and magnolol are the main constituents simultaneously identified in the barks of Magnolia officinalis, which have been used in traditional Chinese medicine to treat a variety of mental disorders including depression. In the present study, we reported on the antidepressant-like effects of oral administration of the mixture of honokiol and magnolol in well-validated models of depression in rodents: forced swimming test (FST), tail suspension test (TST) and chronic mild stress (CMS) model. The mixture of honokiol and magnolol significantly decreased immobility time in the mouse FST and TST, and reversed CMS-induced reduction in sucrose consumption to prevent anhedonia in rats. However, this mixture was unable to affect ambulatory or rearing behavior in the mouse open-field test. CMS induced alterations in 5-hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) levels in various brain regions of rats. An increase in serum corticosterone concentrations and a reduction in platelet adenylyl cyclase (AC) activity were simultaneously found in the CMS rats. The mixture of honokiol and magnolol at 20 and 40 mg/kg significantly attenuated CMS-induced decreases of 5-HT levels in frontal cortex, hippocampus, striatum, hypothalamus and nucleus accumbens. And it markedly increased 5-HIAA levels in frontal cortex, striatum and nucleus accumbens at 40 mg/kg and in frontal cortex at 20 mg/kg in the CMS rats. A subsequent reduction in 5-HIAA/5-HT ratio was found in hippocampus and nucleus accumbens in the CMS rats receiving this mixture. Furthermore, the mixture of honokiol and magnolol reduced elevated corticosterone concentrations in serum to normalize the hypothalamic-pituitary-adrenal (HPA) hyperactivity in the CMS rats. It also reversed CMS-induced reduction in platelet AC activity, via upregulating the cyclic adenosine monophosphate (cAMP) pathway. These results suggested that the mixture of honokiol and magnolol possessed potent antidepressant-like properties in behaviors involved in normalization of biochemical abnormalities in brain 5-HT and 5-HIAA, serum corticosterone levels and platelet AC activity in the CMS rats. Our findings could provide a basis for examining directly the interaction of the serotonergic system, the HPA axis and AC-cAMP pathway underlying the link between depression and treatment with the mixture of honokiol and magnolol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093712     DOI: 10.1016/j.pnpbp.2007.11.020

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  41 in total

1.  Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice.

Authors:  C R Chen; R Tan; W M Qu; Z Wu; Y Wang; Y Urade; Z L Huang
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 2.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

3.  Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice.

Authors:  Wei-Min Qu; Xiao-Fang Yue; Yu Sun; Kun Fan; Chang-Rui Chen; Yi-Ping Hou; Yoshihiro Urade; Zhi-Li Huang
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 4.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors.

Authors:  Mikhail Alexeev; Denise K Grosenbaugh; David D Mott; Janet L Fisher
Journal:  Neuropharmacology       Date:  2012-03-12       Impact factor: 5.250

6.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

7.  Pharmacokinetic and Metabolic Profiling of Key Active Components of Dietary Supplement Magnolia officinalis Extract for Prevention against Oral Carcinoma.

Authors:  Dinh Bui; Li Li; Taijun Yin; Xinli Wang; Song Gao; Ming You; Rashim Singh; Ming Hu
Journal:  J Agric Food Chem       Date:  2020-06-04       Impact factor: 5.279

8.  Therapeutic Action of Honokiol on Postoperative Ileus via Downregulation of iNOS Gene Expression.

Authors:  Taiki Mihara; Shoma Mikawa; Noriyuki Kaji; Mari Endo; Tetsuro Oikawa; Jan Tong-Rong; Hiroshi Ozaki; Masatoshi Hori
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

Review 9.  Stem cell-based neuroprotective and neurorestorative strategies.

Authors:  Chia-Wei Hung; Ying-Jay Liou; Shao-Wei Lu; Ling-Ming Tseng; Chung-Lan Kao; Shih-Jen Chen; Shih-Hwa Chiou; Charn-Jung Chang
Journal:  Int J Mol Sci       Date:  2010-05-05       Impact factor: 5.923

10.  Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

Authors:  Giovanni Vitale; Valentina Ruggieri; Monica Filaferro; Claudio Frigeri; Silvia Alboni; Fabio Tascedda; Nicoletta Brunello; Remo Guerrini; Carlo Cifani; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2009-08-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.